Rigel drops asthma drug after mid-stage study fails
Aug 26 (Reuters) - Rigel Pharmaceuticals Inc said it will stop developing its experimental asthma drug after the therapy failed to improve the lung function of patients in a mid-stage trial.
The inhaled drug, R343, was being tested as a treatment for patients with allergic asthma.
While the drug was shown to be relatively safe and well tolerated, the trial failed to meet any of its goals, Rigel said.
The company said it will review its drug pipeline and will discuss its plans in the 'near-term.'
- U.S. war veteran released by North Korea returns home |
- Pennsylvania newlyweds "just wanted to murder someone together:" police
- U.S. ice storm causes blackouts, delays in Texas, Arkansas
- WTO overcomes last minute hitch to reach its first global trade deal
- China's parliament: Japan has "no right to criticize" air defense zone